GlassScriptPhysician profile
Tyler Champion
NPI 1407350226
$734.01
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $27.78 · 2022: $139 · 2023: $409 · 2024: $158.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $567.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $567.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $129.54 | 2022-2024 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $128.81 | 2022-2023 | Jardiance, Stiolto Respimat, Spiriva Respimat |
| Novartis Pharmaceuticals Corporation | $119.11 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $68.24 | 2024 | Xarelto |
| Merck Sharp & Dohme LLC | $62.49 | 2022-2023 | Recarbrio, Dificid, Zerbaxa |
| Inari Medical, INC. | $54.77 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Alexion Pharmaceuticals, INC. | $45.31 | 2023-2024 | Ultomiris |
| Pfizer INC. | $40.75 | 2021-2022 | |
| Mallinckrodt Hospital Products INC. | $33.35 | 2024 | Terlivaz |
| Astrazeneca Pharmaceuticals LP | $18.44 | 2022 | |
| Recordati_rare_diseases_inc. | $18.04 | 2023 | Panhematin |
| Abbvie INC. | $15.16 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tyler Champion listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.